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Abstract
Objectives: The aim of this study was to evaluate the differences in surgical capacity 
for head and neck cancer in the UK between the first wave (March- June 2020) and 
the current wave (Jan- Feb 2021) of the COVID- 19 pandemic.
Design: REDcap online- based survey of hospital capacity.
Setting: UK secondary and tertiary hospitals providing head and neck cancer surgery.
Participants: One representative per hospital was asked to report the capacity for 
head and neck cancer surgery in that institution.
Main outcome measures: The principal measures of interests were new patient re-
ferrals, capacity in outpatients, theatres and critical care; therapeutic compromises 
constituting delay to surgery, de- escalated surgery and therapeutic migration to non- 
surgical primary modality.
Results: Data were returned from approximately 95% of UK hospitals with a head 
and neck cancer surgery specialist service. 50% of UK head and neck cancer pa-
tients requiring surgery have significantly compromised treatments during the sec-
ond wave: 28% delayed, 10% have received radiotherapy- based treatment instead 
of surgery, and 12% have received de- escalated surgery. Surgical capacity has been 
more severely constrained in the second wave (58% of pre- pandemic level) compared 
with the first wave (62%) despite the time to prepare.
Conclusions: Some hospitals are overwhelmed by COVID- 19 and unable to offer es-
sential cancer surgery, but all have neighbouring hospitals in their region retaining 
good (or even normal) capacity. It is noteworthy that very few patients have been 
appropriately redirected away from the hospitals most constrained by their burden 
of COVID- 19. The paucity of an effective central or regional strategic response to this 
evident mismatch between demand and surgical capacity is to the detriment of our 
head and neck cancer patients.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
© 2021 The Authors. Clinical Otolaryngology published by John Wiley & Sons Ltd.
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1  | OBJEC TIVES
For head and neck (HN) cancers treated by surgery in the first 
wave of the COVID- 19 pandemic between March and June 2020, it 
was evident that surgical and critical care capacity was greatly re-
duced. As a consequence of these constraints, as well as concerns 
over cross- infection with SARS- CoV- 2, HN surgery was minimised, 
de- escalated or avoided in many centres.1 Additionally, many pa-
tients underwent therapeutic migration away from primary sur-
gery.2 The consequences for oncology and functional outcomes 
are unknown but form the focus for an international follow- up to 
COVIDSurg- HN funded by BAHNO (The British Association of 
Head and Neck Oncologists). DATA- CAN estimates3 that UK HN 
cancer referrals fell by up to 60% during the first COVID- 19 spike, 
building a bow wave of undiagnosed upstaging cases. Amongst 
other legacies of the COVID- 19 pandemic, increased mortality and 
compromised functional outcomes for HN cancer patients seem 
certain. The COVIDSurg collaborative established that pulmonary 
complications and mortality were unacceptably high in postop-
erative patients who contracted SARS- CoV- 2 infection,4 but data 
on the safety of HN surgery, even when complex and prolonged, 
proved comparatively reassuring. Risk in elective cancer surgery 
was reduced by around 50% where COVID- 19- free care pathways 
were employed,5 and COVID- 19 occurred after HN surgery in only 
3% of cases,2 with an all- cause 30- day mortality of 1.2%.
A severe second wave of COVID- 19 during winter 2020/21 was 
indeed widely predicted, even during the first wave.6 A plea was 
made for governments to act through preparation of labour, re-
sources and facilities to reduce the burden, not only on COVID- 19 
mortality, but also for other life- limiting conditions including can-
cer.6 Understanding that the backlog in HN cancer is incompletely 
resolved, second- wave surgical capacity appears particularly critical. 
The reassuring data on safety in the first wave reinforce that with 
appropriate testing, PPE and cross- infection measures, HN cancer 
surgery should continue without fear of excess risk, even through a 
period of very high community COVID- 19 incidence.
The aim of this study was to evaluate the differences in surgi-
cal capacity for head and neck cancer in the UK between the first 
(March- June 2020) and the current (Jan- Feb 2021) COVID- 19 pan-
demic waves. Further, we report on efforts in strategic planning and 
mutual aid between hospitals.
2  | DESIGN
REDCap (Research Electronic Data Capture) was employed to record 
all data through its web application. A 13- item survey questionnaire 
(Appendix S2) was constructed according to established survey 
design and conduct guidance.7,8 Both pre- testing and pilot testing 
evaluation of the questionnaire was undertaken by members of the 
COVIDSurg- HN writing group prior to survey distribution.
3  | SET TING AND PARTICIPANTS
A confidential survey was distributed electronically to existing 
COVIDSurg- HN collaborative members, a wide group which had 
collected in excess of 5000 head and neck cancer treatments car-
ried out during March- June 2020.2 All UK HN specialty associations 
were contacted as well as using direct social media. Respondents 
were requested to provide a single response on behalf of their hospi-
tal. Duplicates were reviewed and averaged for subsequent analysis. 
The UK responses were compared with a list of all units providing 
HN cancer surgery (DAHNO).9 Each participating hospital's data re-
ferred to the management of adult patients undergoing HN cancer 
surgery with curative intent.
Keypoints
- 1- week survey, 1 to 8 February 2021, with 62 UK HN cancer surgery hospitals responding, 
indicating around 95% response rate
- 50% of UK HN cancer patients requiring surgery currently having compromised treatment: 
28% delayed, 12% de- escalated, 10% received radiotherapy instead.
- In the worst third of hospitals, 82% of HN cancer patients needing surgery had compromised 
treatment.
- This restriction in capacity is no better than the first wave response, despite advanced warn-
ings for winter 2020/21, and 6 months lead time to prepare the NHS strategic response.
- Hospitals with HN surgical capacity particularly badly affected by COVID- 19 all have neigh-
bouring units with very good capacity— but patients have not generally been redirected
- New HN cancer referrals have picked up from 65% to 80% of pre- COVID level, with some 
units reporting >100%
- Urgent action is needed at central strategic level to manage the “bow wave” of cancers still 
awaited
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4  | MAIN OUTCOME ME A SURES
The survey period was from 1 to 7 February 2021. Respondents 
were requested to complete the survey with estimates of HN cancer 
service capacity at three distinct timepoints:
• prior to the COVID- 19 pandemic.
• during the first peak of COVID- 19 infection (March- June 2020).
• during the current peak of COVID- 19 (January- February 2021).
The entry fields represented either percentage estimates, de-
fined response criteria or direct yes/no responses. In all instances, 
these responses were classified as required fields to complete the 
survey. Data collected included the geographical location of the hos-
pital, access to operating lists, face- to- face versus virtual outpatient 
clinic attendance and degree of access to critical care beds following 
HN cancer surgery. Data were collected regarding operating capac-
ity at alternative hospital sites, and if so whether surgery performed 
by a differing surgical team. We ascertained the extent of delay to 
HN cancer surgery beyond 62- day rule, surgical de- escalation and 
therapeutic migration away from primary surgery. No specific re-
porting guideline was followed.
5  | RESULTS
Data were obtained from 73 individual returns but were incom-
plete for one hospital. Ten hospitals had (understandably) entered 
duplicate data given the multiple channels of communication em-
ployed. In most cases, the duplicate data returned were very closely 
matched and for others represented a difference in caseload be-
tween the ENT and OMFS surgeons entering their own data, so a 
crude mean of the two data entries was employed in these cases. 
By comparison with the DAHNO list9 of HN surgery units, a further 
three UK centres did not provide data, providing a best estimate for 
survey response rate of 95.5%. Following data cleaning, complete 
data on surgical capacity for head and neck cancer for the 62 hospi-
tals are presented.
5.1 | Data summary
Estimates of HN cancer referrals are currently (Jan- Feb 2021) on av-
erage, at 85% of pre- pandemic levels (range 35%- 120%) compared 
with mean 61% (range 20%- 100%) during the first wave in March- 
June 2020. Notably, 5 of the 62 (12%) units report an even higher 
current caseload than prior to the COVID- 19 pandemic, a feature 
not apparent in the first wave in any centre. Theatre capacity was 
slightly lower in the second wave, estimated as a mean 58% (Jan- 
Feb 2021) versus 62% (March- June 2020) of pre- pandemic levels. 
Outpatient appointments carried out face- to- face increased to a 
mean 65% during the second wave, from a mean 46% in the first 




























































































































































































































































































































































































































4  |     SHAW And COLLABORATIVE
have had no access to critical care beds during the second wave, 
and 42% have substantially reduced access. Comparable data for the 
first wave are 15% and 44%, although this is in the context that the 
majority of hospitals (62%, 38/62) reporting occasional difficulty in 
obtaining critical care beds for HN cancer patients prior to the pan-
demic. In the second wave, 30% of HN teams have had at least some 
access to other hospital sites to alleviate pressure from their “usual” 
hospital site, although in only 11% has this required transfer of pa-
tient care for surgery to be performed by another team. This has 
remained consistent throughout differing periods of the pandemic, 
with comparable data for the first wave being 40% and 10%, respec-
tively. Surgery has been delayed in a mean 28% of HN cancer pa-
tients during the second wave, very similar to 30% in the first wave. 
Pre- pandemic delay was only 6% on average. A switch in therapeutic 
modality away from primary surgery is reported in 10% of second- 
wave cases, and surgical de- escalation in 12% second wave, com-
pared with 20% and 17%, respectively, during the first wave.
5.2 | Categorisation by current surgical capacity
Hospitals were categorised by current operating theatre capacity 
for HN cancer: “normal” > = 100% pre- pandemic theatre capac-
ity (15 units, 24%), “reduced” > = 50% and <100% (26 units, 42%); 
“greatly reduced” <50% (21 units, 34%). These data are summarised 
in Table 1. For those units reporting greatly reduced surgical capac-
ity, most also had no access to CCU, and delay to surgery beyond 
62 days was estimated in a mean of 46% of cases, with therapeutic 
compromise in 82% of cases. In contrast, hospitals with normal level 
of capacity understandably had a much lower index of surgical com-
promise (delay 4%, compromise 10%).
5.3 | Categorisation by geographical region
UK hospitals were categorised geographically into 10 regions, and 
their data comparing the impact of surgical capacity on therapeutic 
compromise are presented in Table 2. The regions reported broadly 
similar surgical capacity, ranging between 40% and 75% of pre- 
pandemic levels. However, the impact on therapeutic compromise 
differed greatly by region: delay to surgery between 2% and 62% 
of patients; surgical de- escalation between 0% and 23%; and thera-
peutic migration between 0% and 40% of patients. Regions hosting 
hospitals with surgical capacity that were particularly affected by 
COVID- 19 had neighbouring units with very good capacity main-
tained (Figure 1). This did not appear to result in movement of cases 
between sites nor minimise therapeutic compromises. The distribu-
tion of surgical capacity therefore did not align well with demand. 
The 6 units with less than 5% of their pre- pandemic levels of access 
to operating theatres were spread amongst 5 geographic regions. 
None of these had any current access to CCU, half did not have ac-
cess to operate on alternative sites and two- thirds had not referred 
patients elsewhere.
6  | DISCUSSION
These data show that surgical capacity to treat HN cancer has again 
been severely impacted during the second wave of COVID- 19 during 
January and February 2021. The extent of its impact is broadly com-
parable to the first wave, with one- third of hospitals with greatly re-
duced theatre capacity, a quarter with zero access to postoperative 
critical care. Overall, half of HN cancer patients requiring surgery 
have compromised treatments. The national and regional average 
TA B L E  2   Therapeutic impact to HN cancer surgery categorised by region during Jan/Feb 2021
Theatre Capacity
For HN cancer surgery
% of pre- pandemic level
Therapeutic Compromises
Delay >62 D







Centres Mean capacity Range Mean Range Mean Range Mean Range
All 62 58% 0%- 100% 28% 12% 10%
SE & London 13 75% 30%- 125% 20% 0%- 80% 7% 0%- 50% 20% 0%- 80%
East 3 50% 20%- 100% 60% 0%- 100% 8% 0%- 25% 18% 10%- 25%
South 5 53% 0%- 95% 23% 0%- 150% 10% 0%- 30% 5% 0%- 15%
South West 6 52% 0%- 100% 19% 0%- 50% 0% n/a 0% n/a
Midlands 7 40% 0%- 100% 62% 0%- 100% 22% 0%- 70% 40% 0%- 100%
North West 5 49% 0%- 100% 14% 0%- 25% 1% 0%- 5% 5% 0%- 25%
Yorkshire & North 7 47% 25%- 100% 31% 0%- 80% 17% 0%- 40% 3% 0%- 20%
Scotland 6 60% 0%- 100% 2% 0%- 10% 8% 0%- 50% 0% 0%- 0%
Wales 7 75% 50%- 100% 26% 0%- 50% 20% 0%- 100% 17% 0%- 50%
N. Ireland 3 49% 10%- 85% 53% 10%- 100% 23% 0%- 50% 7% 0%- 20%
The bold was merely to highlight/ signify totals.
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data, however, obscure important and even more troubling detail. 
A minority of hospitals have been completely overwhelmed by pa-
tients suffering with COVID- 19 such that they are unable to offer 
any meaningful HN surgery despite recovering referral pathways 
and resultantly increasing case demand. Unfortunately, the NHS has 
not prepared for redirection of patients away from such hospitals 
where, as a result, the compromises to effective and timely therapy 
are most significant.
This study has been conceived, data have been collected, cleaned 
and analysed, written, peer- reviewed and pre- published within a 2- 
week window. The penetration to UK HN surgery centres has been 
greater than 95%, and colleagues have returned data irrespective of 
regional or specialty allegiances. Once again, the medical profession 
has stepped up to the challenges of COVID- 19 and rapidly estab-
lished new ways to work and collaborate, as amply demonstrated 
by the COVIDSurg2,4,5 collaborative effort. Admittedly, all data 
collected reflect the respondents’ best estimates and some of the 
analyses would be best regarded semi- quantitatively, or as qualita-
tive impressions. There has been no attempt to weigh the data by 
size of unit or HN cancer caseload. There is a risk of false precision 
in “over- analysis” of the reported numerical data, and consequently, 
detailed statistical analyses were unwarranted.
It appears that the UK second COVID- 19 wave is somewhat 
more severe than the first, as evidenced by daily announced death 
rates reaching 1820 early in 2021,10 and COVID- 19 patients NHS 
bed occupancy at around 150% of first wave. Our data show that 
access to critical care for surgical oncology is correspondingly worse 
in the second wave (no access: 26%, reduced access: 42%) than the 
first wave (no access: 18%, reduced access: 47%). This is despite 
efforts to expand intensive care facilities, often at the expense of 
elective capacity. In this context, the ability to sustain only margin-
ally reduced HN cancer theatre capacity (58% vs 62%) is evidence 
that within individual hospital trusts mitigations to maintain surgi-
cal oncology have been partly effective. However, new HN cancer 
F I G U R E  1   Proximity of UK HN surgical 
units with normal >=100% (green), 
reduced >=50% and < 100% (amber) 
and greatly reduced < 50% (red) surgical 
capacity during 2nd wave COVID- 19 
pandemic Jan / Feb 2021
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referrals have picked up from 65% to 80%, with some units reporting 
higher demand than normal pre- pandemic levels. Interestingly, vir-
tual consultations have dropped 65% to 46%. It is speculated that 
surgeon and patient dissatisfaction may be responsible for this fall 
off, or possibly safety concerns regarding missing cancers diagnoses 
without clinical examination in face- to- face clinics.
Despite 6- month preparation time between the waves, half of 
cancer treatments have been significantly compromised during the 
second wave (first wave: 30% delay, 17% RT, 20% de- escalated,total 
67% versus second wave 28%, 10%, 12%, total 50%). Transfer of 
care to other teams remains uncommon. The 10% figure reflects 
data per hospital and presumably translates into a rather lower per-
centage of individual patients actually being transferred. Surgeons 
moving their service to operate at another site is a common miti-
gation in first and second wave and presumably reflects use of the 
private sector or mutual aid from “cold” sites. Of note, surgeons 
were only half as likely to accept de- escalation 20% vs 12%, similarly 
less likely to accept therapeutic migration 17% vs 10%, during the 
second wave. As intuition would predict, units with most severely 
affected surgical capacity also experience the greatest extent of 
therapeutic compromise (82% vs 49% vs 10% in those hospitals with 
greatest reduction, reduced and normal capacity, respectively). For a 
third of hospitals treating HN cancer, their greatly reduced capacity 
reflects a major detrimental effect on cancer treatment, with likely 
significant consequent implications for mortality. Critically, hospi-
tals with most severely constrained surgical capacity all do appear 
to have neighbouring units in the same region maintaining good or 
near- normal capacity, but this has unfortunately not translated into 
widespread transfer of patients.
In the UK, the lead time to prepare for this second wave was 
around 5- 6 months, and with the National Health Service under 
central strategic control, it was presumably plausible, and certainly 
highly desirable, to optimise the available resources. This would have 
minimised consequent rationing of, and delay to, primary surgery for 
HN cancers. Since the start of the pandemic, international and UK ex-
perience has repeatedly shown that the major impacts of COVID- 19 
fall disproportionately upon certain regions and at certain times. 
Anecdotally, one major UK HN unit has been hosted by a hospital bur-
dened by more than 1000 inpatient beds taken by COVID with 200 
of them ventilated. Where this impact coincides with a large volume 
HN surgery centre, perhaps redirection of patient pathways could 
be very effective and should be deployed. The mismatch between 
supply and demand appears to be severe in a significant minority of 
hospitals but has not yet been properly addressed at a central stra-
tegic level, perhaps reflecting lack of capacity and authority to im-
plement such decisive actions. Which bodies have both the required 
data and the authority to implement redistribution of cancer cases for 
best interests of our patients: cancer alliances, NHS trusts, national 
associations? It is not clear to what extent is HN surgery typical of all 
surgical oncology in this respect. HN surgery has a particularly oner-
ous requirement for airway skills, specialist nursing and professions 
allied to medicine and bulky, expensive and fragile specialist equip-
ment such as microscopes, plating kits, lasers and robots. This makes 
moving away from COVID- 19 affected sites logistically complex. It is 
also possible that some surgeons make such a personal interconnec-
tion with their patients early in their care pathway, that there may 
be a cultural resistance to accept another team could achieve similar 
results, and a consequent reluctance to refer on. Conversely, patients 
may also choose to remain with a team they have met or have diffi-
culty travelling to a hospital further afield.
These issues reveal considerable fragility within the NHS, where 
life- critical but elective services can apparently be so vulnerable to 
acute emergency pressures. This lack of resilience in elective care is 
often seen to a lesser extent as “winter pressures,” but not nearly as 
severely as in the current second COVID- 19 wave. The lack of national 
strategic response is of great concern, but it is perhaps not yet too late 
to act. The “bow wave” of delayed HN cancer cases remains ahead of 
us and many more months of COVID- 19 restrictions remain.
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